‎"The initial empirical approach of immunizing with VaxGen's AIDSVax, a recombinant form of the outer glycoprotein-120 (gp120) portion of the HIV envelope, which was based on a strategy that was successful with hepatitis B, failed to protect volunteers from infection, apparently because the vaccine did not induce broadly neutralizing antibodies.3"  

An HIV Vaccine — Challenges and Prospects — NEJM

www.nejm.org

 

More on FAUCI THE FUMBLER:

1. 120518: NYTimes: Trial Vaccine Made Some More Vulnerable to H.I.V., Study Confirms

   http://www.nytimes.com/2012/05/18/health/research/trial-vaccine-made-some-more-vulnerable-to-hiv-study-confirms.html?_r=1&hpw
    
    

   Ya might say the NIH and CDC are "cursed," eh? 

   That would be because they won't come clean about Lyme and LYMErix.

   
    

   Confronting the Cowards Anthony Fauci and Francis Collins:

    

   To: esnyder@hbs.edu  (Harvard Business School Mormon featured in WaPo)
    

   Cc: sr393d@nih.gov, francis.collins@nih.gov, "Allen,Marin (NIH/OD) [E]" <AllenM1@mail.nih.gov>, zach_dann@blumenthal.senate.gov, francis.collins@nih.gov, "Strikas,Raymond A. (Ray) (CDC/OID/NCIRD)" <ras8@cdc.gov>, olib@od.nih.gov, afauci@niaid.nih.gov, joseph.breen@nih.gov, michael.greenwood@yale.edu, richard.horton@lancet.com, astrid.james@lancet.com, spinlyme@yahoogroups.com, roth@blackstone.com, spinlyme@yahoogroups.com, m.zecevic@lancet.com, ideditorial@lancet.com, Lawrence.Tabak@nih.gov, pgauwaerter@gmail.com
   
    

   Subject: Fearless WaPo Leader Anthony Fauci's Patent for Immunosuppression Outcomes like LYMErix Disease
    

    

   Date: May 17, 2012 6:16 AM

   Dear Sir (Harvard Business School's
   http://www.washingtonpost.com/national/on-leadership/if-harvard-business-school-were-a-religion-it-could-be-mormonism/2012/05/11/gIQA04biIU_story.html
   Clayton Christensen),
   
   Since your Harvard and Mormon expertise is
   in "asking the right questions," I ask you
   again to please ask Anthony Fauci if he
   could find out for the nation what OspA,
   the Lyme vaccines (ImmuLyme and LYMErix)
   is.
   
   Remember that Fauci said publically on CNN
   on the Lou Dobbs show that OspA was "scientifically
   a vaccine":
   
   http://edition.cnn.com/TRANSCRIPTS/0306/20/ldt.00.html
   
   "We've had an effective vaccine, but it's the kind of vaccine that you have to essentially vaccinate people each year. And from the standpoint of it's use, it has not been used as efficiently as it could have been used. So scientifically, we had a vaccine and still do have a vaccine, but it's not really well used." -- Anthony Fauci
   
   
   But no one at the NIH, CDC, IDSociety.org, or
   Yale has been able to answer my simple question
   as to what exactly OspA is/was/does.
   
   Now, a few years ago, Anthony Fauci was featured
   in WaPo and the US News and World Report (now owned
   by Mort Zuckerman who was a supporter of the criminal
   Lyme cryme gang, the ALDF.com - the non-non-profit
   who designed the disease, "Lyme" around the outcomes of
   OspA as a vaccine), credited as a "Leader" like yourself:
    
   http://www.washingtonpost.com/wp-dyn/content/video/2009/02/12/VI2009021203091.html
   
   Notice how ^^ Fauci laughs nervously while he explains
   that he has no clue what his scientists are doing,
   making it not too believable that he would be
   recognized as a leader, but then again, this is
   WaPo and the US News.
   
   Specifically, I would like you to note that Anthony
   Fauci owns a patent for a treatment of the immune
   suppression outcomes of diseases like LYMErix Disease
   (the disease caused by LYMErix or exposure to OspA):
   
   - - - - -
   "Illustrative of specific disease states in treatment of which the present invention can be applied are HIV infection and other diseases characterized by a decrease of T-cell immunity, for example, mycobacterial infections like tuberculosis and fungal infections such as cryptococcal disease."
   
   http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5%2C696%2C079.PN.&OS=PN%2F5%2C696%2C079&RS=PN%2F5%2C696%2C079 See More
   United States Patent: 5696079
   patft.uspto.gov
   "A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to ..."
   
   - - - - - -
   
   Meanwhile, there is a new campaign on by the NIH to
   hook up with BigPharma to resuscitate dead near-drugs, but
   still no one mentions publically what either Lyme Disease or
   LYMErix Disease actually is, ***so where would we even start to
   treat these outcomes?***
   
   I have been asking the NIH, CDC, NIAID, Fauci's office,
   IDSociety.org, and Yale over and over again for the
   past 2 months, if anyone could tell us what this
   antigen is, OspA. 
   
   No answer. 
   
   Only, now, a cowardly threat by Francis Collins, the
   fake Catholic.
   
   *WE* know what OspA is, because its structure
   was published in a non-PubMed-linked Korean
   Chemistry journal (Mass-Spec) and more recently
   by the Japanese (NMR).
   
   But the NIH cannot tell us what it is.  They cannot
   publically state what OspA is.  Either they don't
   know or they are afraid to admit the truth.
   
   We believe the latter to be a big possibility - they're
   all cowards - because Francis Collins, the fake-Catholic
   threatened me with "calling the police" if I called
   his office again to report that none of the people who
   work for him can tell me what OspA is.
   
   That kind of behavior is just plain *trashy.*  The NIH
   and CDC said OspA was a vaccine.  But they're going
   to throw me in jail for asking what it is?
   
   This is "Leadership?"
   
   So, we would like you, Mr Harvard Business School
   and Mormon who "asks the right questions" Mr. Christensen 
   to pick up the phone and call Francis Collins and Anthony
   Fauci and ask on our behalf for an answer to the OspA
   question.
   
   Thank you.
   
   Here is Francis Collins' phone number: 301-496-2433 
   
   Kathleen M. Dickson
   former Pfizer Analytical Methods
   Development and Validation chemist
   
    

   --------------------------------

   Once the NIH/CDC publically state what OspA is, that is the end of all "Lyme Disease" guidelines and diagnostic schemas.
   
   The Dearborn "case definition" was used to qualify the outcomes of the OspA vaccines. 

   Once we find out LYMErix or OspA could never have been a vaccine - because the NIH/CDC admit what it is - we will learn that the case definition used to qualify them must be false.
   
   And if Dearborn is false, so too, is Klempner and the "guidelines."

   Everything gets thrown out.  We treat based on the data and evidence available.
   
    

   Is this "Leadership" crap one big circle jerk or what?  They chronically reward and award each other for doing nothing and not being able to think.  Their personalities are like in the new Sasha Baron Cohen movie, The Dictator.
    

   Francis Collins:  "Ask again what OspA is, and I keel you."

    

    

    

    

    

   
    

   120516.htm

   1996; KOREANS : Characterization of Extremely Hydrophobic Immunostimulatory Lipoidal Peptides by Matrix Assisted Laser Desorption Ionization Mass Spectrometry

   Synthetic lipoidal peptides based on viral protein sequences have been prepared. These peptides contain an N-palmitoyl group at the N-terminal residue, which is a modified cysteine, containing a S-[2,3-bis(acyloxy)-(2-R,S)-propyl] moiety. When this residue (Pam3Cys) is at the N-terminus of a synthetic peptide, it acts as potent immunoadjuvant to enhance both IgM and IgG antibody responses to the attached peptide. Conventional analytical procedures (e.g., Edman degradation and amino acid analysis) are either not applicable due to the N-terminal modification, or do not provide confirmation of the intact structure. Chromatographic analysis is also hindered by the tendency of these lipoidal Pam3Cys peptides to form large aggregates, and in some cases to be permanently adsorbed on reversed phase columns. We have applied several mass spectrometric techniques, including fast atom bombardment (FAB), electrospray ionization (ESI) and matrix assisted laser desorption ionization (MALDI) to characterize the intact structures of a number of different Pam3Cys synthetic peptides. The MALDI-MS has been found to be the most sensitive for the analysis of the structure of Pam3Cys peptides. PDF

Intracellular Lyme Grant intended to further the Intracellularity discovered by Mark Klempner in 1992:  "Specifically, we propose to: (1) Characterize the invasion of borrelia burgdorferi into primary fibroblasts. The working hypothesis here is that B. burgdorferi exploits invasion as an additional mechanism to avoid host clearance. Our preliminary studies demonstrate that B. burgdorferi invasion is not dependent on host fibronectin, but does involve ?1 integrins other than... ?5?1. In this Aim we will identify the ??subunit that pairs with ?1 to promote invasion and will also evaluate how B. burgdorferi traffics within these cells; and (2) Determine if invasion is required for B. burgdorferi persistence in vivo. Our working hypothesis is that invasion contributes to persistence by providing an immunoprotected niche for B. burgdorferi. Since Src kinases are required for borrelial internalization in vitro, we will determine whether Src kinase inhibitors aler the infectivity potential of B. burgdorferi in vivo. In addition to standard cultivation and molecuar approaches, novel in vivo imaging will be employed to assess how the inhibitor affects colonization. The overall goal of these studies is to determine the extent in which an intracellula locale contributes to borrelial persistence."
http://projectreporter.nih.gov/project_info_description.cfm?aid=8300386&icde=12284856
 

An Admission that Lyme and LYMErix cause immunosuppression (Tufts, Linden Hu- published with Mark Klempner):
"A better understanding of the workings of innate immunity is important for developing therapies for diseases such as Lyme disease where either an ineffective or an over-exuberant immune response causes the symptoms of illness." 
http://projectreporter.nih.gov/project_info_description.cfm?aid=8228508&icde=12284856&ddparam&ddvalue&ddsub&cr=1&csb=FY&cs=DESC